Perifosine is an oral Akt inhibitor which exerts a marked cytotoxic effect on human tumor cell
lines, and is currently being tested in several phase II trials for treatment of major human …

Background Activated AKT is a marker of decreased event-free or overall survival in
neuroblastoma (NB) patients. The aim of this study was to investigate the effect of perifosine …

Abstract The PI3K/Akt/mTOR pathway is aberrantly active in most human cancers and
contributes to cell growth, proliferation, and survival. Akt is a nodal regulator of cellular …

Akt has been implicated as a molecular determinant of cellular radiosensitivity. Because it is
often constitutively activated or overexpressed in malignant gliomas, it has been suggested …

The serine/threonine kinase Akt, a downstream effector of phosphatidylinositol 3-kinase
(PI3K), is known to play an important role in antiapoptotic signaling and has been implicated …

Diffuse intrinsic pontine glioma (DIPG) is a devastating disease with an extremely poor
prognosis. Recent studies have shown that platelet-derived growth factor receptor (PDGFR) …

Perifosine is an Akt inhibitor displaying strong antineoplastic effects in human tumor cell
lines and is currently being tested in phase II clinical trials for treatment of major human …

Introduction: Perifosine is a novel targeted oral Akt inhibitor currently in Phase III clinical
development for treatment of colorectal cancer (CRC, in combination with capecitabine) and …

Purpose: It is critical to develop methods to quantify the early pharmacodynamic effects of
targeted therapeutics in vivo to make drug development more efficient and ensure …

Abstract Background The PI3K/AKT/mTOR pathway is aberrantly activated in many pediatric
solid tumors including gliomas and medulloblastomas. Preclinical data in a pediatric glioma …